When we last looked at Lantheus in May, its stock was trading just under $80 a share. As a reminder, Lantheus Holdings, Inc.

Analysts raise price forecasts. Lantheus To Buy Evergreen Theragnostics For Over $1 Billion To Bolster Its Cancer Radiopharmaceutical Portfolio Lantheus strengthens its radiopharmaceutical ...

Brian Markison, CEO Evergreen Theragnostics is expected to add Octevy, a registrational stage PET radiodiagnostic that would complement Lantheus' therapeutic candidate, PNT2003. Both acquisitions ...

Evergreen is a clinical-stage radiop Enhances Lantheus’ growth profile with Neuraceq®, a globally approved F-18 PET imaging agent used to detect beta-amyloid plaques in patients evaluated for ...

About Lantheus Holdings, Inc. Lantheus is the leading ... of Life Molecular Imaging Ltd. (“Life Molecular”), and Evergreen Theragnostics Inc. (“Evergreen”), and are based upon current ...

Lantheus is promising up to $1.8 billion in milestone payments to POINT if the two radiotherapeutics get FDA approval and meet commercial objectives, plus royalties on net sales.

B. Riley lowered the firm’s price target on Lantheus (LNTH) to $122 from $127 and keeps a Buy rating on the shares. Competitor Telix’s (TLX) Gozellix received FDA approval for the next ...

Lantheus is enhancing its radiopharmaceutical ... the agreements to acquire Life Molecular and Evergreen Theragnostics. Both acquisitions are expected to close in the second half of 2025, subject ...